Open AccessFirst clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen
Author(s) -
Takahashi Norihiko,
Ohkuri Takayuki,
Homma Shigenori,
Ohtake Junya,
Wakita Daiko,
Togashi Yuji,
Kitamura Hidemitsu,
Todo Satoru,
Nishimura Takashi
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.02106.x
Subject(s) - epitope , carcinoembryonic antigen , cancer , immune system , antigen , medicine , immunotherapy , cancer vaccine , antibody , immunology , peptide vaccine , cancer immunotherapy , metastasis , cancer research
A patient with pulmonary metastasis of colon cancer was treated with artificially synthesized helper/killer‐hybrid epitope long peptide (H/K‐HELP) of MAGE‐A4 cancer antigen. The patient was vaccinated with MAGE‐A4‐H/K‐HELP combined with OK432 and Montanide ISA‐51. There were no severe side‐effects except for a skin reaction at the injection site. MAGE‐A4‐H/K‐HELP induced MAGE‐A4‐specific Th1 and Tc1 immune responses and the production of MAGE‐A4‐specific complement‐fixing IgG antibodies. Tumor growth and carcinoembryonic antigen tumor marker were significantly decreased in the final diagnosis. This is the first report that artificially synthesized MAGE‐A4‐H/K‐HELP induces Th1‐dependent cellular and humoral immune responses in a human cancer patient. ( Cancer Sci 2012; 103: 150–153)